Nibec
나이벡 · 138610
Health Care Pharmaceuticals · KOSDAQ
Market cap US$170.1M (₩234.7B)
Overview
Nibec makes biomaterials used in dental procedures, products that help bone and tissue regenerate after implant surgery.
Its dental regeneration materials are distributed globally through major implant companies and carry regulatory approvals including the U.S. FDA, European CE marking, and China's NMPA. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company's core business is dental tissue-regeneration materials, which it has expanded by developing peptide-fused medical devices and a new bone-graft product it describes as the first of their kind to reach commercialisation.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$11.4M
- FY2024US$17.8M
- FY2025US$23.7M
Operating profit
- FY2023−US$1.6M
- FY2024−US$3.6M
- FY2025US$3.6M
Net income
- FY2023−US$4.6M
- FY2024−US$6.8M
- FY2025US$3.4M
Key ratios (FY2025)
Why it matters
Post-market clinical studies for its collagen regeneration materials are running through Seoul National University Hospital in Korea and a university in Frankfurt, Germany.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?